Get started
Author

Giovanni Luigi Pastorino

Observed names: G.L. Pastorino, Giovanni L. Pastorino, Giovanni Pastorino
ORCID: 0009-0005-7359-3112
Observed ORCID: 0009-0005-7359-3112
OpenAlex ID: A5113370451
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer
2024 · Chiara Mercinelli, Marco Moschini, et al. · Journal of Clinical Oncology · 20
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
2026 · Andrea Necchi, Brigida A Maiorano, et al. · The Lancet Oncology · 17
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study
2025 · B.A. Maiorano, A. Cigliola, et al. · ESMO Open · 3
PDF
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine
2026 · Chiara Mercinelli, Fabrizio Di Costanzo, et al. · Expert Review of Anticancer Therapy · 2
The role of MRI in muscle-invasive bladder cancer: an update from the last two years
2024 · Giovanni Luigi Pastorino, Chiara Mercinelli, et al. · Current Opinion in Urology · 2
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial
2026 · Andrea Necchi, Joep J. de Jong, et al. · Journal of Clinical Oncology · 1
PDF
Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy
2026 · Chiara Mercinelli, Giuseppe Basile, et al. · Clinical Genitourinary Cancer
Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin
2026 · Chiara Mercinelli, Pietro Scilipoti, et al. · JCO oncology advances.
Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC).
2026 · Andrea Necchi, Joep Jacobus de Jong, et al. · Journal of Clinical Oncology
3093P Circulating immune-biomarkers of response to neoadjuvant Sacituzumab Govitecan (SG) alone and with pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC): Secondary analyses from SURE-01 and SURE-02 trials
2025 · G.L. Pastorino, C. Marchigiani, et al. · Annals of Oncology
A0659 – Outcomes of immune-checkpoint inhibitor rechallenge in urothelial carcinoma: Results from a global real-world evidence study
2025 · B.A. Maiorano, A. Cigliola, et al. · European Urology
Outcomes of immune-checkpoint inhibitor rechallenge in urothelial carcinoma: Results from a global real-world evidence study.
2025 · Brigida Anna Maiorano, Antonio Cigliola, et al. · Journal of Clinical Oncology
Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis.
2025 · Brigida Anna Maiorano, Antonio Cigliola, et al. · Journal of Clinical Oncology
PDF
Outcomes of different therapeutic modalities for patients with metachronous oligometastatic renal-cell carcinoma (RCC): Analyses of a single-institution database.
2025 · Antonio Cigliola, Chiara Re, et al. · Journal of Clinical Oncology
PDF
Works count: 14
Citation count: 45
H-index: 3
I10-index: 2
Year
Topic
Type